BACKGROUND: The reduction of cholesterol levels with cholesterol-lowering therapy may improve endothelial function. Lipid-lowering therapy has been greatly enhanced by the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies. Less is known of the effect of PCSK9 inhibitors on endothelial function of subjects with hypercholesterolemia. OBJECTIVE: To assess whether treatment with PCSK9 inhibitors may improve endothelial function evaluated by brachial artery vasoreactivity test. METHODS: Brachial artery vasoreactivity test was performed in 14 consecutive patients with previous myocardial infarction before and after 2 months of therapy with evolocumab 140 mg twice in a month. Mean brachial artery diameter, velocity time integral, flow-mediated dilation (FMD) and low-density lipoprotein (LDL) cholesterol levels were also evaluated. RESULTS: After 2 months of treatment with evolocumab, mean total cholesterol levels decreased from 245 ± 41 to 128 ± 30 mg/dL (P < .001, -48%), and LDL levels from 176 ± 43 to 71 ± 26 mg/dL (P = .001, -59%); FMD conversely increased from 6.3 ± 4.1% to 8.8 ± 6.3% (P = .004, +40%). Improvement in FMD was proportional to reduction of LDL levels (r = 0.69, P = .006). Therapy with evolocumab increased brachial artery diameter during vasoreactivity test (peak values 0.39 ± 0.09 vs 0.36 ± 0.11 cm, P = .010; final values 0.36 ± 0.10 vs 0.34 ± 0.10 cm, P = .001), and velocity time integral (peak levels 96 ± 1 vs 85 ± 9 cm, P = .045). CONCLUSIONS: Two months of treatment with evolocumab 140 mg may improve endothelial function in subjects with increased cardiovascular risk. The improvement in endothelial function is proportional to LDL reduction.
BACKGROUND: The reduction of cholesterol levels with cholesterol-lowering therapy may improve endothelial function. Lipid-lowering therapy has been greatly enhanced by the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies. Less is known of the effect of PCSK9 inhibitors on endothelial function of subjects with hypercholesterolemia. OBJECTIVE: To assess whether treatment with PCSK9 inhibitors may improve endothelial function evaluated by brachial artery vasoreactivity test. METHODS: Brachial artery vasoreactivity test was performed in 14 consecutive patients with previous myocardial infarction before and after 2 months of therapy with evolocumab 140 mg twice in a month. Mean brachial artery diameter, velocity time integral, flow-mediated dilation (FMD) and low-density lipoprotein (LDL) cholesterol levels were also evaluated. RESULTS: After 2 months of treatment with evolocumab, mean total cholesterol levels decreased from 245 ± 41 to 128 ± 30 mg/dL (P < .001, -48%), and LDL levels from 176 ± 43 to 71 ± 26 mg/dL (P = .001, -59%); FMD conversely increased from 6.3 ± 4.1% to 8.8 ± 6.3% (P = .004, +40%). Improvement in FMD was proportional to reduction of LDL levels (r = 0.69, P = .006). Therapy with evolocumab increased brachial artery diameter during vasoreactivity test (peak values 0.39 ± 0.09 vs 0.36 ± 0.11 cm, P = .010; final values 0.36 ± 0.10 vs 0.34 ± 0.10 cm, P = .001), and velocity time integral (peak levels 96 ± 1 vs 85 ± 9 cm, P = .045). CONCLUSIONS: Two months of treatment with evolocumab 140 mg may improve endothelial function in subjects with increased cardiovascular risk. The improvement in endothelial function is proportional to LDL reduction.
Authors: Andrei C Sposito; Ikaro Breder; Joaquim Barreto; Jessica Breder; Isabella Bonilha; Marcus Lima; Alessandra Oliveira; Vaneza Wolf; Beatriz Luchiari; Helison R do Carmo; Daniel Munhoz; Daniela Oliveira; Otavio R Coelho-Filho; Otavio R Coelho; Jose Roberto Matos-Souza; Filipe A Moura; Luiz Sergio F de Carvalho; Wilson Nadruz; Thiago Quinaglia; Sheila T Kimura-Medorima Journal: Cardiovasc Diabetol Date: 2022-08-06 Impact factor: 8.949
Authors: Piotr Pęczek; Mateusz Leśniewski; Tomasz Mazurek; Lukasz Szarpak; Krzysztof J Filipiak; Aleksandra Gąsecka Journal: Life (Basel) Date: 2021-05-23
Authors: Jennifer G Robinson; Kevin Jon Williams; Samuel Gidding; Jan Borén; Ira Tabas; Edward A Fisher; Chris Packard; Michael Pencina; Zahi A Fayad; Venkatesh Mani; Kerry Anne Rye; Børge G Nordestgaard; Anne Tybjærg-Hansen; Pamela S Douglas; Stephen J Nicholls; Neha Pagidipati; Allan Sniderman Journal: J Am Heart Assoc Date: 2018-10-16 Impact factor: 5.501
Authors: Holly C Gooding; Samuel S Gidding; Andrew E Moran; Nicole Redmond; Norrina B Allen; Fida Bacha; Trudy L Burns; Janet M Catov; Michael A Grandner; Kathleen Mullan Harris; Heather M Johnson; Michaela Kiernan; Tené T Lewis; Karen A Matthews; Maureen Monaghan; Jennifer G Robinson; Deborah Tate; Kirsten Bibbins-Domingo; Bonnie Spring Journal: J Am Heart Assoc Date: 2020-09-30 Impact factor: 5.501
Authors: Thomas Metzner; Deborah R Leitner; Gudrun Dimsity; Felix Gunzer; Peter Opriessnig; Karin Mellitzer; Andrea Beck; Harald Sourij; Tatjana Stojakovic; Hannes Deutschmann; Winfried März; Ulf Landmesser; Marianne Brodmann; Gernot Reishofer; Hubert Scharnagl; Hermann Toplak; Günther Silbernagel Journal: Biomedicines Date: 2022-01-11